Member Info for mulledwine

Russell Taylor, CEO of ITE Group plc, commented: "ITE has delivered record results reflecting a strong operational performance as we execute against our stated strategy. Over the year, we have seen a return of economic growth in our core markets, and have invested for future growth by acquiring three complementary businesses, which add strength and breadth to our existing portfolio of market leading events ITE operates in resilient markets and has made a good start to the current financial year. Trading is in line with our expectations and we are well placed to continue our growth, both organically and through selective acquisitions."

Record results reflect strong organic growth with a contribution from new acquisitions · Return to economic growth in the Russian & CIS markets · Completed three acquisitions, adding new sectors and geographies to ITE's business · Strong cash generation: - net cash of £5.5m at year-end after investments of circa £50m · Final dividend increased to 4.2p (2010: 4.0p); full year dividend of 6.1p (2010: 5.7p) · £93m of revenues booked for 2012: 8%+ ahead of last year on a like-for-like basis

http://www.investegate.co.uk/Article.aspx?id=201111290700199314S

Rio Tinto is among the select group of companies that can reasonably be considered mining bellwethers. It is, therefore, useful to pay attention to its comments on the goings-on in the resources world, claims the Investment Column in The Independent, adding that the latest noises have been less than bullish. Rio's chief executive, Tom Albanese, warned that "continuing stresses in the Eurozone and a weaker outlook for the US economy are inevitably affecting customer sentiment, which has become more negative in recent months". Despite this, the Indy sticks with its "buy" recommendation as the long term trend towards greater consumption of commodities remains intact.

Shares in platinum refiner Johnson Matthey are a "hold", reckons Questor in the Daily Telegraph. The shares are down 12% so far this year since they were recommended at £20.38 at the start of January, despite an impressive financial performance as investors continue to worry about the global outlook. The shares are trading on March 2012 earnings multiple of 13.1 times, falling to 12.3 next year. Given the continuing market uncertainty, the shares are a hold for now until we get some clarity on the euro.

The timing is auspicious for Senior’s purchase of Airbus-parts supplier Weston, as the market for large commercial aircraft is just starting to take off, notes Tempus in The Times. The deal, at £54m, or the equivalent of one year’s sales or eight times’ annual earnings, might look an expensive one, but otherwise it ticks all the right boxes, and reduces Senior's dependence on Boeing as a major customer. Senior shares have had a good run over the past couple of years and had added another 2¾p to 165p by last night. They sell on about 11 times’ earnings, which does not look overly cheap, but they remain among the better-placed in their sector.

Just when I thought that Dongfang was an odds on no brainer for the coveted “most dodgy aim float for 2011” award, our own Richard Gill introduced me to a worthy contender. Radiant Growth (radg) came to the aim market in September at 10p as a start up investment company with a vague oriental remit. The shares were placed with some dubious sounding Asian entities and insiders. There is in effect no float. The company has announced one half baked sounding investment to do with buoys and the shares trade at 60p to give less than £6 million cash and one £100,000 investment in a buoy project a value of over £60 million . How crazy is that? If readers can think of any contenders more worthy of contention than radg or Dongfang please let me know. The winner will be announced at the year end.

http://sharecrazy.com/beta/daily/6238/the-sharecrazy-most-dodgy-aim-float-of-2011-award-2-contenders

The Sharecrazy “most dodgy AIM float of 2011” award - 2 contenders by East London’s most feared short seller, Lucian Miers A month ago I wrote about aim fiasco Dongfang and promised an update. Since then the shares have collapsed on a massive profits warning, but with a market cap of £80 million are still grotesquely overvalued. I managed to track down Mr. Ismail the finance director who confirmed to me that me the only security for the $73 million owed to the company by chief executive Chen Tongkao, is his shareholding in the company which is held by brokers Northland Capital. He also intimated that the carrying value of the company’s property is understated on the balance sheet. I would argue that the opposite is much more likely to be the case and that the banks’ chances of getting their money back are zero.

http://sharecrazy.com/beta/daily/6238/the-sharecrazy-most-dodgy-aim-float-of-2011-award-2-contenders

UBS has downgraded its rating on children’s and parenting products retailer Mothercare from neutral to sell and slashed its target price by over three quarter after assessing the group’s first half results published two weeks ago. “Management is reviewing the size and scope of the UK business, announcing its conclusions in early 2012. We expect the market to remain competitive and only cost savings will prevent the UK loss from increasing,” UBS said. While the broker believes that ongoing international store growth will continue, international LFL sales are expected to “deteriorate”.

Prime Markets recommends buying shares in IG Group, saying that the European sovereign debt crisis creates “ideal conditions” for the spread-betting firm. The group said this morning that it has continued to see high levels of client activity during its second quarter and first half revenues will be 23% higher than last year. “With market moving sovereign debt news items an almost daily occurrence, IG Group should be able to sustain the current levels of revenue growth, and in the run up to the next trading statement on 13 December, Prime Markets believes that near perfect conditions exist for a retest of October 475p highs in the run up to the Dec trading statement,” said head of dealing at Prime Markets, Richard Curr.

Zambeef rolls forward 28/11/2011 Ben Jaglom Agricultural concern Zambeef Products (ZAM) has reported a surge in pre-tax profits thanks to a buoyant Zambian market. The AIM-quoted concern, which joined the junior market this June in an IPO that raised £33.7 million at 38.06p a year in a dual listing on AIM and the Lusaka Stock Exchange, declared pre-tax profits of $10.6 million (2010: $3.3 million) on sales of $206.8 million for the year to September. Gross margins rose from 31.4 per cent to 34.1 per cent while earnigns per share of 5.1 cents (2010: 2.62 cents) were announced. In an interview with Growth Company Investor Irish chief executive officer and co-founder Francis Grogan enthused that he 'Didn't think there was a better country in the world' than Zambia, insisting that with a buoyant economy and a recent 'peaceful transition of power' (President Michael Sata took power this year after winning an election against incumbent Rupiah Banda) there was 'nowhere we would rather be'. Finance director Sushmit Maitra added to the enthusiasm, arguing that a 'rapidly growing middle class' in the country will help fuel demand for its beef, pork and chicken products. Regarding progress in Nigeria the company noted its partner Shoprite wanted to open 'six new stores between Nigeria and Ghana' in the coming year adding that it has acquired agricultural land to the north of the Nigerian capital of Lagos. Analysts at Religare are forecasting pre-tax profits of $20.9 million (EPS: 8 cents) on sales of $228 million for the year to September 2012. Last recommended by Growth Company Investor this October at 44.5p the shares currently trade at 52p. A company with diverse interests ranging from beef to edible oils to a tannery, in addition to an expansive retail operation, its range of businesses represent a considerable strength in a sector that often disappoints investors unused to the tumultous effects on profits of factors such as turbulent weather. Its key test remains its ability to expand from its position as a national heavyweight in Zambia to growing in regional superpower Nigeria. We retain our long-term buy rating.

http://www.growthcompany.co.uk/news/1675938/zambeef-rolls-forward.thtml

Collins Stewart initiates buy on Domino's Pizza, target price 460p.

Collins Stewart downgrades Immunodiagnostic Systems from buy to hold, target price cut from 939p to 789p

28th November 2011 Analyst: Steven Moore Email:steven.moore@gecr.co.uk Tel: 0207 562 3362 Sanderson Group – Positive Full-Year Results; reiterate ‘Buy’ at 26p, Target Price: 54p

Nah - surely this will recover - must be a 10-20% rise from here short term - up a quid by Friday !

Outlook As we announced at the time of our full year results in June, we expect the demand for vitamin D testing will continue to grow, albeit at lower rates than experienced in recent years. This appears to be the case with growth continuing in both manual and automated testing. The impending introduction of competing automated products from some major manufacturers has coincided with efforts to contain health budgets, particularly in the USA. As a result we are beginning to see increasing price pressure, particularly on our larger accounts, and some disruption to equipment ordering patterns which we believe will persist in the short term and it is likely that this will impact negatively on our placement rate for the current period. As we noted earlier there are a number of global account discussions that are underway although the likely outcome and duration of these discussions remains uncertain. The company is continuing to follow its strategy of driving growth by the introduction of new tests onto the IDS-iSYS. We now have 10 automated products available for sale outside of the USA, with five of these products also available for sale in the USA. We believe that the wider test menu available will increase the attractiveness of the system to our identified market segment and become a key differentiator of the system. We expect to be the first to market by launching our automated test for 1,25 vitamin D in the coming 6 months. We also expect to launch our automated tests for Renin and Aldosterone which are key markers in the diagnosis of hypertention before the end of June 2012. Development of other IDS-iSYS tests for BioPTH, TRAP and other markers is progressing as expected. In addition we are seeing continued strong interest from third party companies who are keen to explore licensing opportunities for additional automated assays and we would expect to report progress on this during the current financial period. We have strengthened our Sales and Marketing teams and our plans to establish joint ventures in the major emerging markets will accelerate as a result of the additional resource and focus on these areas. Despite some short term pressure the overall prospects for the Group are good. The recurring nature of our revenues will allow us to progress our plans to grow both organically and by acquisition where this is consistent with the Group's stated product strategy.

Operational Highlights: · 81 IDS-iSYS systems placed or sold in H1 - 23% up on the same period last year (2010: 66) · 322 IDS-iSYS units placed or sold in total - up 33.6% on 30 March 2011 · Average revenue per system is now £90,000 compared to £77,000 in September 2010 · Launch of PTH (1-34) test for osteoporosis therapy on the IDS-iSYS · 10 automated assays available for sale outside the USA · 5 automated assays available for sale in the USA · Signed distribution agreement giving access to US Government market.